



Company Overview

CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases with limited to no treatment options. In November 2022, CohBar announced that it had initiated a process to explore and review a range of strategic alternatives.

CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)

Nov 27 2023, 6:05 PM EST

CohBar Reports Second Quarter 2023 Financial Results

Aug 14 2023, 4:01 PM EDT

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

Jun 5 2023, 8:05 AM EDT

Stock Overview

Symbol	CWBR
Exchange	Nasdaq
Market Cap	2.62m
Last Price	\$0.90
52-Week Range	\$0.58 - \$6.90

04/19/2024 10:29 AM EDT

Management Team

Joseph J. Sarret, M.D., J.D.

Chief Executive Officer and Director

CohBar, Inc.

1455 Adams Drive
Suite 1308
Menlo Park, CA 94025

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

